Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 10/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374720 | 1.00 | F10 (0.58) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL6376598 | 1.00 | F10 (0.58) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL6374223 | 0.97 | F10 (0.56) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL6374212 | 0.97 | F10 (0.56) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL6374263 | 0.97 | F10 (0.56) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL5433595 | 0.91 | F10 (0.56) | F10TSHRLMNAHPGDMAPT | |
| SCHEMBL5434232 | 0.87 | F10 (0.60) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL5429178 | 0.87 | F10 (0.74) | F10TSHRFPR2LMNAHPGD | |
| SCHEMBL6376266 | 0.86 | FPR1 (0.55) | FPR2 | |
| SCHEMBL5428324 | 0.86 | F10 (0.59) | F10TSHRFPR2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | claimed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | claimed |
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | F10 4/4885TSHR 1409/4885FPR2 766/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | F10 117/4885TSHR 587/4885FPR2 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.